Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease

References

• MunkholmPLangholzEDavidsenMBinderVFrequency of glucocorticoid resistance and dependency in Crohn’s diseaseGut19943533603628150347
   PubMed Web of Science ®Google Scholar
• ModiglianiRMaryJYSimonJFClinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Thérapeutique des Affections Inflammatoires DigestivesGastroenterology19909848118182179031
   PubMed Web of Science ®Google Scholar
• McDonaldJWTsoulisDJMacdonaldJKFeaganBGMethotrexate for induction of remission in refractory Crohn’s diseaseCochrane Database Syst Rev201212CD00345923235598
   PubMed Web of Science ®Google Scholar
• PearsonDCMayGRFickGHSutherlandLRAzathioprine and 6-mercaptopurine in Crohn disease. A meta-analysisAnn Intern Med199512321321427778826
   PubMed Web of Science ®Google Scholar
• SandbornWSutherlandLPearsonDMayGModiglianiRPranteraCAzathioprine or 6-mercaptopurine for inducing remission of Crohn’s diseaseCochrane Database Syst Rev20002CD00054510796557
   PubMedGoogle Scholar
• TarganSRHanauerSBvan DeventerSJHA short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s diseaseN Engl J Med199733715102910359321530
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJRutgeertsPHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trialGastroenterology2006130232333216472588
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology20071321526517241859
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGStoinovSCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med2007357322823817634458
   PubMed Web of Science ®Google Scholar
• SchreiberSKhaliq-KareemiMLawranceICMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med2007357323925017634459
   PubMed Web of Science ®Google Scholar
• BehmBWBickstonSJTumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s diseaseCochrane Database Syst Rev20081CD00689318254120
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJReinischWInfliximab, azathioprine, or combination therapy for Crohn’s diseaseN Engl J Med2010362151383139520393175
   PubMed Web of Science ®Google Scholar
• LowenbergMD’HaensGNovel targets for inflammatory bowel disease therapeuticsCurr Gastroenterol Reports2013152311
   Google Scholar
• SandbornWJAbreuMTD’HaensGCertolizumab pegol in patients with moderate to severe Crohn’s disease and secondary failure to infliximabClin Gastroenterol Hepatol201088688695 e220451663
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• TrinchieriGPflanzSKasteleinRAThe IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responsesImmunity200319564164414614851
   PubMed Web of Science ®Google Scholar
• GeeKGuzzoCChe MatNFMaWKumarAThe IL-12 family of cytokines in infection, inflammation and autoimmune disordersInflamm Allergy Drug Targets200981405219275692
   PubMedGoogle Scholar
• ToussirotEMichelFBéreauMBindaDUstekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementPatient Prefer Adherence2013736937723641151
   PubMed Web of Science ®Google Scholar
• MannonPJFussIJMayerLAnti-interleukin-12 antibody for active Crohn’s diseaseN Engl J Med2004351202069207915537905
   PubMed Web of Science ®Google Scholar
• PelusoIPalloneFMonteleoneGInterleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implicationWorld J Gastroenterol200612355606561017007011
   PubMed Web of Science ®Google Scholar
• NeurathMFIL-23: a master regulator in Crohn diseaseNat Med2007131262817206128
   PubMed Web of Science ®Google Scholar
• DuerrRHTaylorKDBrantSRA genome-wide association study identifies IL23R as an inflammatory bowel disease geneScience200631458041461146317068223
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBTimansJCXuYHunteBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity200013571572511114383
   PubMed Web of Science ®Google Scholar
• IwakuraYIshigameHThe IL-23/IL-17 axis in inflammationJ Clin Invest200611651218122216670765
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGFedorakRNA randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s diseaseGastroenterology200813541130114118706417
   PubMed Web of Science ®Google Scholar
• ToussirotEThe IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseasesInflamm Allergy Drug Targets201211215916822280236
   PubMedGoogle Scholar
• CroxtallJDUstekinumab: a review of its use in the management of moderate to severe plaque psoriasisDrugs201171131733175321902296
   PubMed Web of Science ®Google Scholar
• KruegerGGLangleyRGLeonardiCA human interleukin-12/23 monoclonal antibody for the treatment of psoriasisN Engl J Med2007356658059217287478
   PubMed Web of Science ®Google Scholar
• LeonardiCLKimballABPappKAEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)Lancet200837196251665167418486739
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGLebwohlMEfficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Lancet200837196251675168418486740
   PubMed Web of Science ®Google Scholar
• GottliebAMenterAMendelsohnAUstekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialLancet2009373966463364019217154
   PubMed Web of Science ®Google Scholar
• McInnesIBKavanaughAGottliebABEfficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialLancet2013382989478078923769296
   PubMed Web of Science ®Google Scholar
• Janssen Research and Development, LLCA Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) Available from: http://clinicaltrials.gov/ct2/show/NCT01369329. NLM identifier: NCT01369329Accessed March 6, 2014
   Google Scholar
• Janssen Research and Development, LLCA Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease (UNITI-2) Available from: http://clinicaltrials.gov/ct2/show/NCT01369342. NLM identifier: NCT01369342Accessed March 6, 2014
   Google Scholar
• Janssen Research and Development, LLCA Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease (IM-UNITI) Available from: http://clinicaltrials.gov/ct2/show/NCT01369355. NLM identifier: NCT01369355Accessed March 6, 2014
   Google Scholar
• LebwohlMLeonardiCGriffithsCELong-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trialsJ Am Acad Dermatol201266573174121930328
   PubMed Web of Science ®Google Scholar
• GordonKBPappKALangleyRGLong-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsJ Am Acad Dermatol201266574275121978572
   PubMed Web of Science ®Google Scholar
• PappKAGriffithsCEGordonKLong-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upBr J Dermatol2013168484485423301632
   PubMed Web of Science ®Google Scholar
• ReichKSchenkelBZhaoNUstekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2J Dermatol Treat2011226337347
   PubMed Web of Science ®Google Scholar
• LangleyRGFeldmanSRHanCUstekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trialJ Am Acad Dermatol201063345746520462664
   PubMed Web of Science ®Google Scholar
• GuentherLHanCSzaparyPImpact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trialsJ Am Acad Dermatol2011257851857
   Web of Science ®Google Scholar
• PanniccioneRSandborneWGordonGBriakinumab (ABT874) for treatment of Crohn’s diseaseLate breaking abstract presented at: 18th United European Gastroenterology Week (UEWG)October 23–27 2010Barcelona, Spain Abstract OP051D
   Google Scholar